Mostrar el registro sencillo del ítem

dc.contributor.authorArias, Fabio
dc.contributor.authorFranco Moltabán, Francisco
dc.contributor.authorRomero Pérez, Miguel 
dc.contributor.authorCarrión Peregrina, María Dora 
dc.contributor.authorCamacho Quesada, Encarnación 
dc.date.accessioned2021-11-24T11:55:33Z
dc.date.available2021-11-24T11:55:33Z
dc.date.issued2021-08-15
dc.identifier.citationF. Arias et al. Synthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors. Bioorganic & Medicinal Chemistry 44 (2021) 116294. [https://doi.org/10.1016/j.bmc.2021.116294]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/71721
dc.descriptionThis work was supported by the grant from Comisión Interministerial de Ciencia y Tecnología, Ministerio de Economía y competitividad (MINECO) (SAF2017-84894-R), with funds from the European Union, and by the Ministerio de Economia y Competitividad, Instituto de Salud Carlos III (CIBER-CV).es_ES
dc.descriptionThe authors also thank the Centro de Supercomputación de la Universidad de Granada (CSIRC) for the computing resources and the Granada University Library for the financial support to the APC.es_ES
dc.description.abstractIn search of new Nitric Oxide Synthase (NOS) inhibitor agents, two isosteric series of derivatives with an imidamide scaffold (one of them with a hydroxyl group and the other with a carbonyl one) were synthesized and evaluated on inducible (iNOS) and neuronal (nNOS) isoforms. These compounds have been designed by combining a kynurenamine framework with an amidine moiety in order to improve selectivity for the inducible isoform. In general, the in vitro inhibitory assays exhibited better inhibition values on the iNOS isoform, being the N-(3-(2-amino-5-methoxyphenyl)-3-hydroxypropyl)-4-(trifluoromethyl)benzimidamide 4i the most active inhibitor with the highest iNOS selectivity, without inhibiting eNOS. Docking studies on the two most active compounds suggest a different binding mode on both isozymes, supporting the experimentally observed selectivity towards the inducible isoform. Physicochemical in silico studies suggest that these compounds possess good drug-likeness properties.es_ES
dc.description.sponsorshipCSIRCes_ES
dc.description.sponsorshipCentro de Supercomputación de la Universidad de Granadaes_ES
dc.description.sponsorshipGranada University Libraryes_ES
dc.description.sponsorshipEuropean Commissiones_ES
dc.description.sponsorshipMinisterio de Economía y Competitividad SAF2017-84894-Res_ES
dc.description.sponsorshipInstituto de Salud Carlos IIIes_ES
dc.description.sponsorshipComisión Interministerial de Ciencia y Tecnologíaes_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectDrug designes_ES
dc.subjectInhibitorses_ES
dc.subjectImidamideses_ES
dc.subjectNitric Oxide Synthasees_ES
dc.subjectSynthesis es_ES
dc.titleSynthesis, bioevaluation and docking studies of new imidamide derivatives as nitric oxide synthase inhibitors.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España